Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor
Copyright © 2020 Translational and Clinical Pharmacology..
Type 2 diabetes mellitus is a multifactorial condition characterized by high level of sugar in the blood. To control hyperglycemia, combination therapy is recommended if monotherapy fails to achieve glycemic control. The combination of a dipeptidyl peptidase-4 (DPP-4) inhibitor and a sodium-glucose cotransporter type 2 (SGLT2) inhibitor is a promising option of the combination therapies in terms of safety as well as efficacy. Despite of the value of combination therapy of these two agents, the pharmacokinetic drug interactions between these two classes of agents have been evaluated in a few drugs. Thus, we reviewed the potential pharmacokinetic drug interaction based on the in vitro metabolism- and transporter-mediated drug interaction information as well as drug interaction studies in human, between a DPP-4 inhibitor and a SGLT2 inhibitor which are marketed in South Korea.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Translational and clinical pharmacology - 28(2020), 1 vom: 31. März, Seite 17-33 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gu, Namyi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dipeptidyl-peptidase IV inhibitors |
|---|
| Anmerkungen: |
Date Revised 28.09.2020 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.12793/tcp.2020.28.e4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30859522X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30859522X | ||
| 003 | DE-627 | ||
| 005 | 20231225132049.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.12793/tcp.2020.28.e4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1028.xml |
| 035 | |a (DE-627)NLM30859522X | ||
| 035 | |a (NLM)32274378 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gu, Namyi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2020 Translational and Clinical Pharmacology. | ||
| 520 | |a Type 2 diabetes mellitus is a multifactorial condition characterized by high level of sugar in the blood. To control hyperglycemia, combination therapy is recommended if monotherapy fails to achieve glycemic control. The combination of a dipeptidyl peptidase-4 (DPP-4) inhibitor and a sodium-glucose cotransporter type 2 (SGLT2) inhibitor is a promising option of the combination therapies in terms of safety as well as efficacy. Despite of the value of combination therapy of these two agents, the pharmacokinetic drug interactions between these two classes of agents have been evaluated in a few drugs. Thus, we reviewed the potential pharmacokinetic drug interaction based on the in vitro metabolism- and transporter-mediated drug interaction information as well as drug interaction studies in human, between a DPP-4 inhibitor and a SGLT2 inhibitor which are marketed in South Korea | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Dipeptidyl-peptidase IV inhibitors | |
| 650 | 4 | |a Drug interaction | |
| 650 | 4 | |a Pharmacokinetics | |
| 650 | 4 | |a Sodium-glucose transporter 2 inhibitors | |
| 700 | 1 | |a Park, Sang-In |e verfasserin |4 aut | |
| 700 | 1 | |a Chung, Hyewon |e verfasserin |4 aut | |
| 700 | 1 | |a Jin, Xuanyou |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, SeungHwan |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Tae-Eun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Translational and clinical pharmacology |d 2017 |g 28(2020), 1 vom: 31. März, Seite 17-33 |w (DE-627)NLM306497387 |x 2289-0882 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2020 |g number:1 |g day:31 |g month:03 |g pages:17-33 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.12793/tcp.2020.28.e4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2020 |e 1 |b 31 |c 03 |h 17-33 | ||